Patient-Centered Outcomes Research Institute
Treatment of Multiple Sclerosis PFA - Cycle 3 2015
- May I contact someone at PCORI about the suitability of my proposed project?
- What types of costs will PCORI cover?
- What are PCORI’s guidelines for treatment cost/coverage?
- How should the proposal address patient and stakeholder engagement?
- Should I include references in my LOI?
- How will LOIs be evaluated?
- We have received a number of questions about the Study Advisory Committee (SAC) requirement in the targeted and pragmatic PFAs for Cycle 3 2015, and how this requirement should be managed. See below for more information.
- For a study comparing health system–level interventions where the primary analyses are patient-centered outcomes, can funding be used to conduct secondary analyses of economic impacts?
- What do you mean by “powering the study for subgroups of interest”?
- Will an interaction test be less powerful than subgroup-specific tests? If you can demonstrate that an intervention can work in a variety of subgroups, is it required to demonstrate how those effects differ between subgroups?
- Would financial incentives to patients to increase medication adherence be an appropriate comparison intervention?
- If I have a design that compares the effectiveness of two alternatives, would it be acceptable to include usual care as a third arm?
- Can one comparative-treatment intervention be a new option for patients? For example, can it be enhanced care based on the literature but not currently in routine practice?
- What if there is no recent systematic review on the research gap that my research study will address?
- As a secondary aim, can I propose to measure treatment costs but not compare them? Or should I refrain from this area entirely, except for patient costs?
- Can my proposed study address the priority research question, but only for a specific population?
- Is this a one-time solicitation?